Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "gut microbiota and epithelial cells" interface denotes a critical, dynamic interaction between the community of microorganisms inhabiting the gastrointestinal tract and the specialized epithelial cells lining the gut. Epithelial cells construct chemical and physical barriers, secrete immunological mediators, and interact with the microbiota through metabolites, cellular adhesion molecules, and signaling pathways. The crosstalk regulates immune responses, barrier integrity, and microbial composition, thereby influencing health and disease, including inflammatory, metabolic, and neoplastic conditions. This interface is a focus for emerging therapies such as probiotics, dietary modifications, and fecal microbiota transplantation, but cannot be considered a traditional pharmacological target (e.g., receptor, enzyme).
Modulation of microbial composition (probiotics/antibiotics); Enhancement of barrier function (metabolites, SCFAs); Immune modulation (altering cytokine/chemokine output); Restoration of homeostasis (FMT, prebiotics)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota and epithelial cells.